MedTrace Logo

A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever

NCT03830684 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-02-05

No results posted yet for this study

Summary

This study in order to evaluate the Baicalein Tablets' safety and efficiency for audit with influenza

Conditions

Interventions

DRUG

Baicalein Tablets 400mg

4 Baicalein Tablets and 2 placebo per time, three times a day

DRUG

Baicalein Tablets 600mg

6 Baicalein Tablets per time, three times a day

DRUG

blank control 0mg

6 placebo per time, three times a day

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qingquan Liu, Professor · Beijing Chinese Medicine Hospital affiliated to Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-05-31
Completion
2019-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830684 on ClinicalTrials.gov